A potential mechanism underlying atypical antipsychotics-induced lipid disturbances

Metabolic syndrome in people with schizophrenia: a review

(2015) MARC DE HERT et al.   World Psychiatry

The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals

(2012) Young-Ah Moon et al.   Cell Metabolism

SREBPs: regulators of cholesterol/lipids as therapeutic targets in metabolic disorders, cancers and viral diseases

(2012) Amy K Walker et al.   Clinical Lipidology

Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver

(2011) Emilie Lauressergues et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat

(2011) Goran Jassim et al.   PSYCHOPHARMACOLOGY

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

(2010) W. Wolfgang Fleischhacker et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes

(2010) Emilie Lauressergues et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men

(2010) Coleman Gross et al.   Obesity

Insulin-induced gene: A new regulator in lipid metabolism

(2010) Xiao-Ying Dong et al.   PEPTIDES

Gene–gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

(2010) Y-J Liou et al.   PHARMACOGENOMICS JOURNAL

A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model

(2010) Heidi N. Boyda et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Mifepristone treatment of olanzapine-induced weight gain in healthy men

(2009) Coleman Gross et al.   ADVANCES IN THERAPY

Aripiprazole

(2009) Shubhra Mace et al.   CNS DRUGS

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

(2009) R. W. Buchanan et al.   SCHIZOPHRENIA BULLETIN

Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia

(2009) Mihael H. Polymeropoulos et al.   SCHIZOPHRENIA RESEARCH

Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients

(2008) Audun O. Vik-Mo et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

(2008) S Le Hellard et al.   MOLECULAR PSYCHIATRY

PGRMC1 (progesterone receptor membrane component 1): A targetable protein with multiple functions in steroid signaling, P450 activation and drug binding

(2008) Hannah J. Rohe et al.   PHARMACOLOGY & THERAPEUTICS

Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver

(2008) Johan Fernø et al.   PSYCHOPHARMACOLOGY

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

(2008) Marc De Hert et al.   SCHIZOPHRENIA RESEARCH

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL

Progesterone receptor membrane component 1—Many tasks for a versatile protein

(2007) R LOSEL et al.   STEROIDS